Comparing newer treatments for pediatric inflammatory bowel disease
Part of Digestive system clinical trials.
This study is for children and teens with inflammatory bowel disease (Crohn's, colitis, or indeterminate) whose previous anti-TNF medicine stopped working. It compares several newer treatments to see which works best.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be younger than 18 years old.
- You must have Crohn's disease, ulcerative colitis, or indeterminate colitis.
- You must have tried at least one anti-TNF medicine (like infliximab, adalimumab, or certolizumab) and it stopped working for you.
- You must be planning to start a new medicine: vedolizumab, ustekinumab, risankizumab, guselkumab, mirikizumab, tofacitinib, or upadacitinib (or a biosimilar).
- You cannot have taken any of these new medicines before.
- You cannot have had your colon removed or currently have an ostomy (a surgical opening in your belly).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a combination of immune-suppressing treatments for children with Crohn’s disease that is not well controlled. It may help reduce inflammation and improve symptoms if you meet the study’s disease-activity and safety requirements.
This study follows children newly diagnosed with Crohn’s disease to see how results from scans and endoscopy (camera scope) relate to outcomes over the first year. It may help doctors choose better early treatment plans and monitor children more effectively.
This study looks at people with active Crohn's disease or ulcerative colitis starting a new type of medication (anti-TNF, ustekinumab, upadacitinib, or vedolizumab), as well as people without IBD having a routine colonoscopy. It aims to collect information to better understand how these treatments work.
This trial tests whether people with Crohn’s disease or ulcerative colitis who are currently well-controlled can safely use less-frequent anti-TNF medicine. It may help reduce treatment intensity while keeping inflammation under control.
This study compares an existing UC medication (infliximab) with a newer one (ustekinumab) and a combination of both. The goal is to see which works best for moderate to severe UC when other treatments have failed.
This trial compares three types of medications (vedolizumab, ustekinumab, and JAK inhibitors) in people with ulcerative colitis who have already tried an anti-TNF drug but still have active disease. The goal is to see which treatment works best as a second option.
Hear when a new Ulcerative Colitis, Pediatric trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.